Effector mechanisms in demyelinating neuropathies

被引:0
|
作者
Hartung, HP
Zielasek, J
Jung, S
Toyka, KV
机构
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
While the cause of the immune-mediated neuropathies (Guillain-Barre syndrome, GBS; CIDP; multi-focal motor neuropathy and paraproteinemic neuropathies) remains elusive considerable progress has been made in delineating the effector mechanisms that underlie myelin destruction, In GBS circulating antibodies to glycolipids possibly precipitated by an antecedent Campylobacter jejuni infection can be detected with high frequency, These antibodies may interfere with neuromuscular transmission and eventuate myelin damage by activating the complement system, providing for the generation of chemotactically active split products C3a and C5a, the opsonin C3b, and assembly of the membrane attack complex. Such antibodies may also, via binding to the Fe receptor, target macrophages to the a myelin sheath. Corroborative evidence for a crucial pathogenic role of antibody-mediated complement activation is also available for the MAG-associated neuropathies, Macrophages as decisive effector cells of myelin damage may also act by releasing injurious molecules such as oxygen radicals. nitric oxide metabolites. proteases, eicosanoids and cytokines. Demyelinative as well as degenerative actions have been described for the cytokines TNF-a and lymphotoxin. Increased understanding of the effector mechanisms underlying demyelination may aid in developing more efficacious treatments for this group of neuropathies.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 50 条
  • [41] Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: Treatment update
    Steck, Andreas J.
    Czaplinski, Adam
    Renaud, Susanne
    NEUROTHERAPEUTICS, 2008, 5 (04) : 528 - 534
  • [42] Optic and auditory pathway dysfunction in demyelinating neuropathies
    Knopp, M.
    Leese, R. J.
    Martin-Lamb, D.
    Rajabally, Y. A.
    ACTA NEUROLOGICA SCANDINAVICA, 2014, 130 (01): : 53 - 57
  • [43] Apheresis in treatment of the inflammatory demyelinating peripheral neuropathies
    Kincaid, JC
    THERAPEUTIC APHERESIS, 2002, 6 (01): : 53 - 56
  • [44] Atypical varieties of chronic inflammatory demyelinating neuropathies
    Dyck, PJ
    Dyck, PJB
    LANCET, 2000, 355 (9212): : 1293 - 1294
  • [45] Update on the management of chronic inflammatory demyelinating neuropathies
    Leger, J. M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S48 - S48
  • [46] Hereditary demyelinating neuropathies: from gene to disease
    Hanemann, CO
    NEUROGENETICS, 2001, 3 (02) : 53 - 57
  • [47] Hereditary demyelinating neuropathies: from gene to disease
    C.O. Hanemann
    Neurogenetics, 2001, 3 : 53 - 57
  • [48] Chronic immune-related demyelinating neuropathies
    Nemni, R
    Sessa, M
    EUROPEAN JOURNAL OF NEUROLOGY, 1996, 3 (03) : 177 - 185
  • [49] Down-stream effects in demyelinating neuropathies
    Kwa, M. S. G.
    Chandler, D. C.
    Jonge, R. R.
    ten Asbroek, A. L. M. A.
    King, R. H. M.
    Kalaydjieva, L.
    Baas, F.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2007, 12 : 47 - 48
  • [50] Multiple sclerosis and peripheral multifocal demyelinating neuropathies
    Kim, J. Y.
    Kwon, J. Y.
    Park, Kee Duk
    MULTIPLE SCLEROSIS, 2009, 15 (01): : 148 - 148